Biography | With 13 years experience in the academic and research fields, El Tayebi is an assistant professor of Molecular Toxicology and Pharmacoeconomics and she is leading the “Molecular Pharmacology Research Group-MPRG” in the faculty of Pharmacy and Biotechnology, German University in Cairo (GUC), Egypt. El Tayebi received her B.Sc. degree with highly honored excellence from faculty of Pharmacy and Biotechnology, GUC, in 2008. In 2009, she has been appointed as assistant lecturer of molecular pathology and pathophysiology at the GUC. And in 2014, she started teaching Cell Biology and Genetic Engineering as an assistant professor. She pursued her M.Sc. and PhD studies in the field of Molecular Pharmacology in the period from 2008-2012. She received her PhD degree with “Summa cum laude” from the GUC in collaboration with the institute of Pathology, Heidelberg, Germany in 2012. Hend established the Molecular Pharmacology research group- MPRG at the GUC in 2015. The MPRG focuses on pharmacogenomics of tumors and autoimmune diseases via epigenetic and molecular immuno-regulation of certain immuno-modulatory proteins in different cancers as well as autoimmune diseases such as Multiple Sclerosis. El Tayebi has supervised 20+ MSc. And PhD projects as well as B.Sc biotechnology project. The research group is composed of 2 PhD student, 20 M.Sc. students, 2 B.Sc. students and 10 undergraduate interns. MPRG is collaborating with several research groups worldwide in Germany, Netherlands and USA. Through out her academic career, Hend has been invited as a guest speaker in more than 10 international conferences in Europe and MENA region, published and presented her research work in 30+ international conferences in Europe and USA (EASL, AASLD, Falling Wall of Berlin, ESMO, EMBO and more) and she has published 20+ paper publications in a high impact peer-reviewed international journals. In 2015, She has pursued her MBA studies at the German university in Cairo with a double major of “International Business” and “Strategic Management”. Additionally, she studied Health Economics and research outcome in Utrecht university, the Netherlands in addition to the Arab Academy for Science and Transportation-AAST, Egypt where she received a diploma in health economics studies from. El Tayebi has been awarded the AAST award for achieving the 1st Rank on all AAST diploma programs in February 2020. | Research Interests | The Molecular Pharmacology Research Group focuses on genetic and epigenetic immunooncology and molecular regulation of certain immuno-modulatory proteins in liver and breast cancer as well as autoimmune diseases such as Multiple Sclerosis (MS). The team collaborates with several departments in the faculty of pharmacy and biotechnology at the GUC such as pharmaceutical biology (investigating the role of novel nutraceuticals on diseases epigenome), pharmaceutical chemistry (pharmacologic screening, testing and evaluation of novel compounds) and pharmaceutical technology (establishment of novel delivery systems and targeted therapies). El Tayebi has received several funds from DAAD and STDF. |
Publications2023| Journal 2023 | MicroRNA 155 modulation of CD8+ T cell activity personalizes response to disease modifying therapies of patients with relapsing remitting multiple sclerosis. Elkhodiry AA, Zamzam DA, El Tayebi HM.Med Int (Lond). 2023 Mar 20;3(2):20. doi: 10.3892/mi.2023.80. eCollection 2023 Mar-Apr.PMID: 37032715 Free PMC article. | | Journal 2023 | Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study. Amin NS, Abd El-Aziz MK, Hamed M, Moustafa RR, El Tayebi HM.Front Immunol. 2023 Feb 17;14:1087595. doi: 10.3389/fimmu.2023.1087595. eCollection 2023.PMID: 36883100 | | Journal 2023 | More gain, less pain: How resistance training affects immune system functioning in multiple sclerosis patients: A review. Amin NS, El Tayebi HM.Mult Scler Relat Disord. 2023 Jan;69:104401. doi: 10.1016/j.msard.2022.104401. Epub 2022 Nov 12.PMID: 36403379 Review. | | Grant 2023 | “Comprehensive screening and in-vitro analysis of PD-L1 small molecule inhibitors on a myriad of solid tumors: Hepatocellular carcinoma, colon cancer, pancreatic cancer and triple negative breast cancer” funded by the DAAD-BMBF | | Grant 2023 | Screening of Resistance- and Relapse-related Single Nucleotide Polymorphism in Hepatocellular Carcinoma Patients. (Project ID: 46300) Funded by the STDF | | Grant 2023 | Multi-dimensional screening of potential PD-1/PD-L1 immune checkpoint inhibitors as anti- hepatocellular carcinoma agents.” funded by ASRT |
2022| Journal 2022 | NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer. Hussein NH, Eissa RA, de Bruyn M, El Tayebi HM.Life Sci. 2022 Jun 15;299:120523. doi: 10.1016/j.lfs.2022.120523. Epub 2022 Apr 2.PMID: 35378140 | | Journal 2022 | CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer. Ghallab AM, Eissa RA, El Tayebi HM.Front Pharmacol. 2022 Apr 20;13:862125. doi: 10.3389/fphar.2022.862125. eCollection 2022.PMID: 35517812 | | Journal 2022 | A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach. Amer HT, Eissa RA, El Tayebi HM.Front Mol Biosci. 2022 Oct 28;9:1032517. doi: 10.3389/fmolb.2022.1032517. eCollection 2022.PMID: 36387279 | | Journal 2022 | The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer. Amer HT, Stein U, El Tayebi HM.Cancers (Basel). 2022 Nov 7;14(21):5460. doi: 10.3390/cancers14215460.PMID: 36358879 | | Journal 2022 | Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Kamal MA, Mandour YM, Abd El-Aziz MK, Stein U, El Tayebi HM.Molecules. 2022 Aug 28;27(17):5537. doi: 10.3390/molecules27175537.PMID: 36080304 |
2021| Grant 2021 | Principle investigator of Academy of Scientific Research and Technology (ASRT) fund for project entitled: “Multi-dimensional screening of potential PD-1/PD-L1 immune checkpoint inhibitors as anti- hepatocellular carcinoma agents.” Proposal accepted in May 2021 | | Grant 2021 | Principle investigator of DAAD/BMBF grant in collaboration with Prof. Ulrike Stein (Charite and Max-Delbruck Centre, Berlin, Germany). Project entitled: “CXCR2 Small Molecule Inhibitors: a Novel Approach to Combat Chemo-resistance and Augment Immunotherapy in Triple Negative Breast Cancer” Proposal accepted in December 2021. | | Journal 2021 | From Whole Blood to Isolated Pro-Metastasis Immune Cells: An Ex Vivo Approach to Isolate and Manipulate Immune Cells Contributing to Tumor Metastasis. Samir A, El Khodiry AA, ElTayebi HM. Methods Mol Biol. 2021 ;2294:209-218. doi: 10.1007/978- 1- 0716-1350-4_15.PMID: 33742404 | | Journal 2021 | Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology. Hamed MM, Handoussa H, Hussein NH, Eissa RA, Abdel-Aal LK, El Tayebi HM.Life Sci. 2021 Mar 30;277:119353. doi: 10.1016/j.lfs.2021.119353. Online ahead of print.PMID: 33798547 | | Journal 2021 | miR-155 and functional proteins of CD8+ T cells as potential prognostic biomarkers for relapsing-remitting multiple sclerosis Aya A Elkhodiry, Dina A Zamzam, Hend M El Tayebi , Mult Scler Relat Disord. 2021 Aug;53:103078. doi: 10.1016/j.msard.2021.103078. Epub 2021 Jun 11. | | Journal 2021 | Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes. Samir A, Tawab RA, El Tayebi HM.Oncol Lett. 2021 Aug;22(2):593. doi: 10.3892/ol.2021.12854. Epub 2021 Jun 7.PMID: 34149904 | | Journal 2021 | Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Atwa SM, Odenthal M, HM El Tayebi.Cancers (Basel). 2021 Aug 27;13(17):4343. doi: 10.3390/cancers13174343.PMID: 34503153 | | Journal 2021 | Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis.Elkhodiry AA, El Tayebi HM.Noncoding RNA Res. 2021 Dec 7;6(4):187-199. doi: 10.1016/j.ncrna.2021.12.002. eCollection 2021 Dec.PMID: 34938929 | | Journal 2021 | Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients? Elgohary S, Elkhodiry AA, Amin NS, Stein U, El Tayebi HM.Cells. 2021 Feb 2;10(2):302. doi: 10.3390/cells10020302.PMID: 33540625 | | Conference 2021 | CXCR2 Small Molecule Antagonists: a Novel Approach to Enhance the Effect of PDL-1 Inhibitors in Triple Negative Breast Cancer, ESMO Breast Cancer Virtual Congress, May 2021. Alaa Ghallab , Reda A. Eissa and Hend M. El Tayebi | | Conference 2021 | CXCR2 Antagonist Revoked TGF- β Elevation in Chemo-resistant Triple Negative Breast Cancer Cells. ESMO ImmunOncology Conference, Geneva, December 2021 Alaa Ghallab, Reda Eissa, Hend M. El Tayebi | | Conference 2021 | Combined efforts of LncRNAs DILC and Atezolizumab to regulate MMP-9 release in tumor microenvironment of TNBC TAMs and cells lines. ESMO ImmunOncology Conference, Geneva, December 2021. Amany Samir, Reda Eissa, Ulrike Stein, Hend M. El Tayebi | | Conference 2021 | Paracrine Crosstalk between LncRNA DILC and TNF-α release in tumor microenvironment of triple negative breast cancer Amany Samir, Reda Eissa, Ulrike Stein, Hend M. El Tayebi. ESMO ImmunOncology Conference, Geneva, December 2021 |
2020Journal 2020 | LncRNAs; XIST and MALAT1 hijack PD-L1 regulatory pathway in breast cancer subtypes. Amany Samir, Reda A. Eissa and Hend M. El Tayebi, Oncology Letters, December 2020 (In production and Proofreading) | | Journal 2020 | GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets Nada H. Hussein, Nada S. Amin and Hend M. El Tayebi* , Front. Oncol., 04 December 2020 | https://doi.org/10.3389/fonc.2020.537311 | | Journal 2020 | Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. Sara M Atwa, Heba Handoussa, Karim M Hosny, Margarete Odenthal and Hend M El Tayebi, World Journal of Hepatology, October 2020 (ahead of print) | | Journal 2020 | MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer. Barsoum FS, Awad AS, Hussein NH, Eissa RA, El Tayebi HM.Pathol Res Pract. 2020 Nov 4;216(12):153274. doi: 10.1016/j.prp.2020.153274. Online ahead of print.PMID: 33171372 | | Journal 2020 | XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients Esraa A Salama, Reda E Adbeltawab, Hend M El Tayebi, Front Oncol, 9, 1459 2020 Jan 10. PMID: 31998636, PMCID: PMC6966712 DOI: 10.3389/fonc.2019.01459 | | Journal 2020 | Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. Atwa SM, Handoussa H, Hosny KM, Odenthal M, Tayebi HME.World J Hepatol. 2020 Dec 27;12(12):1211-1227. doi: 10.4254/wjh.v12.i12.1211.PMID: 33442449 | | Conference 2020 | Virtual Screening and biological evaluation of potential PD-1/PD-L1 immune checkpoint inhibitors as anti-hepatocellular carcinoma agents. American Association for the Study of Liver Diseases, AASLD Congress November 2020. Monica A. Kamal , Yasmine M. Mandour , Hedy A. Badry , Dalia Omran , Hend I. Shoushaa, Ashraf O. Abdelaziz, and Hend M. El Tayebi | | Conference 2020 | Tackling TGF-β mediated Doxorubicin Chemoresistance by AZD5069 in Triple Negative Breast Mammospheres. ESMO Congress, September 2020 (Virtual) Alaa Ghallab , Reda A. Eissa and Hend M. El Tayebi | | Conference 2020 | Abrogation of Taxol® Chemo-resistance via Epigenetic Immune Checkpoints Regulation in Triple Negative Breast Cancer. ESMO Breast Cancer May 2020, Berlin. S. El Shihy, M. Armanious, R. Abdeltawab and H. M. El Tayebi | | Conference 2020 | MALAT-1 ruling the miR-182/PIG-C/MSLN triad in triple negative breast cancer ESMO Breast Cancer May 2020, Berlin. A. Samir, F. Barsoum, R. Abdeltawab and H. M. El Tayebi | | Book Chapter 2020 | Book Chapter titled: From whole blood to isolated pro-metastasis immune cells: an exvivo approach to isolate and manipulate immune cells contributing to tumor metastasis. Book name: Nature Protocols. Accepted March 2020 (in Online Publication process) |
2019Journal 2019 | Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Waly AA, El-Ekiaby N, Assal RA, Abdelrahman MM, Hosny KA, El Tayebi HM, Esmat G, Breuhahn K, Abdelaziz AI. Front Physiol. 2019 Jan 24;9:1918. doi: 10.3389/fphys.2018.01918. eCollection 2018. PMID: 30733684 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353855/ | | Conference 2019 | NEAT-1: culprit LncRNA tying PIG-C, MSLN, CD80 in TNBC.ESMO congress 2019, Barcelona N.H. Hussein, H.M. El Tayebi, M. de Bruyn, Annals of Oncology (2019)30(suppl_5): v760-v796. 10.1093/annonc/mdz268. | | Conference 2019 | Pivotal role of XIST in regulating immune checkpoint PD-1/PD-L1 through a shared pathway between miR-194-5p and miR-155-5p in Hepatocellular carcinoma. EASL HCC Summit 2019, Lisbon. S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi |
| Conference 2019 | NEAT-1: culprit LncRNA tying PIG-C, MSLN, CD80 in TNBC.ESMO congress 2019, Barcelona N.H. Hussein, H.M. El Tayebi, M. de Bruyn, Annals of Oncology (2019)30(suppl_5): v760-v796. 10.1093/annonc/mdz268. | | Conference 2019 | Pivotal role of XIST in regulating immune checkpoint PD-1/PD-L1 through a shared pathway between miR-194-5p and miR-155-5p in Hepatocellular carcinoma. EASL HCC Summit 2019, Lisbon. S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi |
2018Journal 2018 | Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis.El Khodiry A, Afify M, El Tayebi HM.World J Gastroenterol. 2018 Feb 7;24(5):549-572. doi: 10.3748/wjg.v24.i5.549. Review.PMID:29434445 | Conference 2018 | Paradoxically functioning onco-miR-155 and the tumor suppressor miR-194 consensus on PD-L1 immune checkpoint upregulation via MALAT1 and XIST in hepatocellular Carcinoma. April 2018, Journal of Hepatology, The International Liver Congress, EASL 2018.S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi | | Book Chapter 2018 | “Non-Coding RNAs as Future Cancer Biomarkers” Salama E.A. and El Tayebi H.M. Book name: Cancer Therapy Publisher: MedDocs International | | Book Chapter 2018 | "The Era of Immunotherapy in Breast Cancer” Samir, A. and El Tayebi H.M. Book name: Cancer Therapy Publisher: MedDocs International | | Conference 2018 | PIG-C and SOCS3; potential immunotargets regulated by non-coding RNAs in TNBC Dec 2018, ESMO Immuno-Oncology Congress. Monia Mohsen, Reda Abdeltawab and Hend M. El Tayebi |
2017Journal 2017 | Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Shaalan YM, Handoussa H, Youness RA, Assal RA, El-Khatib AH, Linscheid MW, El Tayebi HM, Abdelaziz AI. Nat Prod Res. 2017 Aug 18:1-4. doi: 10.1080/14786419.2017.1366478. [Epub ahead of print]PMID:28817968 | Journal 2017 | MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients.Rahmoon MA, Youness RA, Gomaa AI, Hamza MT, Waked I, El Tayebi HM, Abdelaziz AI. Growth Factors. 2017 Jun;35(2-3):76-87. doi: 10.1080/08977194.2017.1354859. Epub 2017 Jul27.PMID:28747084 | Conference 2017 | 43PXIST and TSIX: Novel cancer-immune biomarkers showing differential expression in tumor, PBMCs, serum, nipple discharge and lymph nodes of PD-L1 overexpressing BC patients. Dec 2017, Annals of Oncology, E Atef R Abdel Tawab Hend M. El Tayebi | Conference 2017 | 42PDifferential expression of PD-L1, MALAT1 and XIST in tumors and lymph nodes of TNBC and IDC patients and their regulation by miR-182. Dec 2017, Annals of Oncology, A Samir R Abdel Tawab, Hend M. El Tayebi | Conference 2017 | Regulation of PD-L1 immune check point by onco-miR-155 via LncRNA-MALAT-1 expression manipulation in hepatocellular carcinoma.Nov. 2017, EMBL. S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi | Conference 2017 | Long non-coding RNAs, MALAT-1 and XIST: novel immune check point regulators manipulating PDL-1 expression under the control of mir-182 in breast cancer. Nov. 2017, EMBL, A. Samir R Abdel Tawab, Hend M. El Tayebi |
2016Journal 2016 | miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma.Yacoub RA, Fawzy IO, Assal RA, Hosny KA, Zekri AN, Esmat G, El Tayebi HM, Abdelaziz AI. J Clin Transl Hepatol. 2016 Dec 28;4(4):300-305. doi: 10.14218/JCTH .2016.00031. Epub 2016 Dec 27.PMID:28097098 | Journal 2016 | MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. Youness RA, El-Tayebi HM, Assal RA, Hosny K, Esmat G, Abdelaziz AI. Oncol Lett. 2016 Oct;12(4):2567-2573. Epub 2016 Jul 27.PMID:27698829 | | Journal 2016 | Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.Habashy DA, El Tayebi HM, Fawzy IO, Hosny KA, Esmat G, Abdelaziz AI. World J Hepatol. 2016 Aug 18;8(23):976-84. doi: 10.4254/wjh.v8.i23.976.PMID:27621763 | Journal 2016 | Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression.Youness RA, Rahmoon MA, Assal RA, Gomaa AI, Hamza MT, Waked I, El Tayebi HM, Abdelaziz AI.Growth Factors. 2016 Aug;34(3-4):128-40. doi: 10.1080/08977194. 2016.1200571. Epub 2016 Jul 8. | Review 2016 | Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma. El Tayebi H M, Abdelaziz A I, World Jorunal of Gastroenetrology, March 2016 (ahead of print) | Conference 2016 | 29PXIST overrides the regulatory effect of miR-194 on its immunomodulatory target PD-L1 in breast cancer. Nov 2016, Annals of Oncology, Marwa Hamed R.A.E. Eissa Lobna Kassem Hend M. El Tayebi | | Conference 2016 | Restoring The Expression of Endogenous IGF-1 by miR-486 in NK Cells of HCC Patients Augments Its Cytotolytic Activity Against Hepatoma Cell Lines Apr 2016, Journal of Hepatology– EASL International Liver Congress, Barcelona, Spain. Rana A. Youness, Mai A. Rahmoon, Asmaa Gomaa, Imam Waked, Hend M El Tayebi., Ahmed I. Abdelaziz | | Conference 2016 | miR-155: A Double Faced microRNA With Respect to its impact on Tumorigenesis in Both Natural Killer Cells and Their Target Hepatocytes Apr 2016, Journal of Hepatology– EASL International Liver Congress, At Barcelona, Spain. Mai A. Rahmoon,Rana A. Youness, Asmaa Gomaa, Imam Waked, Hend M. El Tayebi, Ahmed I. Abdelaziz, |
2015Journal 2015 | miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma.Fawzy IO, Hamza MT, Hosny KA, Esmat G, El Tayebi HM, Abdelaziz AI. FEBS Lett. 2015 Aug 4;589(17):2257-65. | Conference 2015 | Modulating the Expression of the Activating Receptor NKG2D and the Inhibitory Receptor NKG2A of NK cells by miR-182 in HCC. Mohamed M. Abdelrahman*, Injy O. Fawzy, Asmaa I. Gomaa, Imam Waked, Gamal Esmat, Hend M. El Tayebi, Ahmed I. Abdelaziz..5th Clinical Epigenetics International Meeting March 5th - 6th, 2015, Düsseldorf, Germany | Conference 2015 | IMPROVING NATURAL KILLER CELLS CYTOTOXICTY AND HARNESSING HEPATOCYTE CANCER PROGRESSION BY MIR-486-5P. Aya A. Bassiouni* , Mai A. Rahmoon1, Rana A. Youness, Asmaa I. Gomaa, Imam Waked, Gamal Esmat3, Hend M. El Tayebi, Ahmed I. Abdelaziz. European Associaton for the study of Liver, Vienna, EASL 2015 (Poster Presentation). | | Book 2015 | "miR-486-5p and Liver Cancer Therapy: A Beautiful Mind Act” Rana Ahmed youness. Hend M. El Tayebi • Asmaa I. Gomaa • Imam Waked • Gamal Esmat • Ahmed Ihab AbdelAziz Published by: Lambert Academic Publishing (LAP) | | Book 2015 | “miR-615 and miR-155: microRNAs governing HCC in a paradoxical manner” Hend M. El Tayebi , PhD and Ahmed I. Abdelaziz, MD,PhD. |
2014Journal 2014 | Transcriptional activation of IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. El Tayebi H.M., Waly A.A., Assal R.A., Hosny K.A., Esmat G. and Abdelaziz A.I., Oncology Letters, (November 2014) | Journal 2014 | A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p & miR-182-5p on IGF-1R, IGFBP-3 and IGF-II in Hepatocellular carcinoma. R. A.Assal , H. M.El Tayebi , K. A. Hosny , G.Esmat , A. I. Abdelaziz, Molecular Medicine Reports (June 2014) | Journal 2014 | miR-155 induces mTOR expression via activation of IGF-II/IGF-1R axis and inhibitionof IGFBP-3 in Hepatocellular Carcinoma.. Hend M. El Tayebi; Amr A. Waly; Rana A. Youness; Mai A. Rahmon; Aya A. Bassiouni; Reem A. Assal; Karim A. Hosny; Gamal Esmat; Ahmed I. Abdelaziz.. American Association for Cancer Research (AACR), Philadelphia, USA. September 2014 (Poster Presentation) | Conference 2014 | A coach, a playmaker, a defender and strikers: an epigenetic-target interplay in HCV/HCC.M.M. Fouad, N.M. Elemam, H.B. Sherif, S.A. El Sobky, R.A. Yacoub, A.K. Abelhamid, T. Elbaz, M.A. Mohey El Din , I.O. Fawzy , H.M. El Tayebi ,N. El-Ekiaby, R.Y. Mekky, G. Esmat ,A.I. Abdelaziz.European Associaton for the study of Liver, London, EASL 2014 (Poster Presentation). | Conference 2014 | Unshielding IGF-II mRNA by targeting IGF2BPs through demethylating the Let-7a-3 gene in HCC cell lines. Waly A.A. ,El Tayebi H.M., Hosny K.A., Esmat G. and Abdelaziz A.I.HCC Summit, EASL, Geneva 2014 |
2013Journal 2013 | A Missing Correlation between the Number and Type of MEFV Mutations and Severity of Clinical Manifestations in Egyptian Pediatric FMF Patients. Injie O. Fawzy*, Hend M. El. Tayebi*, Menna M. El. Wassal, Farah H. El. Bibany, Samia Salah, Ahmed I. Abdelaziz , British Journal of Medicine and Medical Research, 2013. | Journal 2013 | Detection of Y chromosome microdeletions in recurrent abortions among Egyptian females using SYBR Green Real Time PCR. Said M.M, Fahmi A.A, Hemeda H.M, Aly B, AbdelAal R.H, Nasr S.M, El Gamal M, Fawzy I.O, El Tayebi H.M, Abdelaziz A.I , Journal of American Science , 2013. | Journal 2013 | Repression of miR-17-5p with elevated expression of E2F-1 and c-MYC in non-metastatic Hepatocellular Carcinoma and enhancement of cell growth upon reversing this expression pattern. H M El Tayebi, K Omar, S Hegy, M El Maghrabi, M El Brolosy, K A Hosny, G Esmat, A I Abdelaziz , Biochemical and Biophysical Research Communications, 2013. | Conference 2013 | Failure of induction of the oncomiRic cluster miR-182/miR-96 in HCV-induced non-metastatic hepatocellular carcinoma tissues renders them as markers for metastasis.Asal R.A., El Tayebi H.M., Hosny K.A., Esmat G. and Abdelaziz A.I. European Society of Pathology, Lisbon 2013 (Oral presentation) | Conference 2013 | MicroRNA-17-5p promotes tumorgenesis through the repression of IGFBP-3 and enhancement of Insulin-like growth factor signaling. Habashy D.A., El Tayebi H.M., Hosny K.A., Esmat G. and Abdelaziz A.I.European Society of Pathology, Lisbon 2013 (Poster presentation) | Conference 2013 | Hypermethylation of MicroRNA let-7a-3 Gene Represses the Primary and Mature let-7a-3 with an Inverse Corelation to IGF-II mRNA in HCV-induced Hepatocellular Carcinoma. Waly A., El Tayebi H.M., Hosny K.A., Esmat G. , and Abdelaziz A.I.. European Associaton for the study of Liver, Amesterdam, EASL 2013 (Poster Presentation | | Book 2013 | “miR-615-5p and miR-155-5p in Hepatocellular Carcinoma Immunotherapy” Mai Atef, Rana Ahmed youness, Hend M. El Tayebi, Asmaa I. Gomaa, Imam Waked, Gamal Esmat, Ahmed Ihab AbdelAziz Published by: Lambert Academic Publishing (LAP) |
2012Journal 2012 | miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma.
H M El Tayebi, K A Hosny, G Esmat, K Breuhahn, Ahmed Ihab Abdelaziz , FEBS letters , 2012. | Conference 2012 | E2f-1 Transcript Knock Down via oncomiR-17-5p gain of function in Hepatocellular Carcinoma Cell Lines. El Tayebi H.M., Omar K., Hosny K.A., Esmat G. and Abdelaziz A.I.Humboldt Kolleg “Pharmaceutical and Biotechnological Therapies” September 2012 (Poster presentation) | Conference 2012 | MiR-155 is an inducer for the insulin-like growth factor II mitogenic signaling pathway in HCV-progressed hepatocellular carcinoma.H.M. El Tayebi, K.A. Hosny, G. Esmat, K. Breuhahn, A.I. Abdelaziz.,European Associaton for the study of Liver, Barcelona, EASL 2012 (Poster Presenation). |
2011Journal 2011 | Expression of Insulin-like Growth Factor-II, Matrix Metalloproteinases and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. El Tayebi H, Salah W, El Sayed I, Zekri AR , Zayed N, Salem S, Esmat G and Abdelaziz AI : , Biomarkers, 2011. |
2010Conference 2010 | Positive correlation between the up-regulated Matrix Metalloproteinases and their down-regulated tissue inhibitors with the clinical staging of Hepatocellular Carcinoma Patients. El Tayebi H.M, Salah W., Elsayed I.H., Zekri A., Esmat G. and Abdelaziz A.I. , ICMCO, 2010. |
2009Conference 2009 | Dysregulation of the Overexpressed Insulin like growth Factor II (IGFII) by Tissue inhibitor of Metalloproteinases (TIMP1) in the peripheral blood of Patients with Hepatocellular Carcinoma. Eltayebi H, Zekri Abdelrahman and Abdelaziz AI : , 5th APASL Single topic conference, 2009. |
|